Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 6/20 | 0.65 |
| ▸ | CTSB | P07858 | 4/20 | 0.65 |
| ▸ | CTSS | P25774 | 2/20 | 0.64 |
| ▸ | TACR1 | P25103 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7028199 | 1.00 | CTSL (0.65) | CTSLCTSBCTSSTACR1 | |
| SCHEMBL14513407 | 1.00 | CTSL (0.65) | CTSLCTSBCTSSTACR1 | |
| SCHEMBL8259359 | 0.95 | CTSL (0.70) | CTSLCTSBCTSSTACR1 | |
| SCHEMBL23234615 | 0.95 | CTSL (0.70) | CTSLCTSBCTSSTACR1 | |
| SCHEMBL4409560 | 0.95 | CTSL (0.70) | CTSLCTSBCTSSTACR1 | |
| SCHEMBL3132335 | 0.90 | CTSB (0.60) | CTSLCTSBCTSSTACR1 | |
| SCHEMBL7436543 | 0.90 | CTSB (0.60) | CTSLCTSBCTSSTACR1 | |
| SCHEMBL7028811 | 0.90 | CTSL (0.68) | CTSLCTSB | |
| SCHEMBL7028808 | 0.90 | CTSL (0.68) | CTSLCTSB | |
| SCHEMBL19015908 | 0.90 | CASP3 (0.60) | CTSLCTSBCTSSTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026089565-A1 | USE OF CATHEPSIN L INHIBITOR IN COMBINATION ADMINISTRATION | 연세대학교 산학협력단 | 2026-04-30 | — | — | WO | claimed |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO., INC. (US) | 2023-05-11 | — | — | US | claimed |
| EP-4149552-A1 | COMPOSITIONS AND METHODS FOR INCREASING EFFICACY OF A DRUG | Healion Bio, Inc. (US) | 2023-03-22 | — | — | EP | claimed |
| US-20220143128-A1 | METHODS FOR TREATING TRAUMATIC BRAIN INJURY | BCELL SOLUTIONS, INC. (US) | 2022-05-12 | — | — | US | claimed |
| WO-2022072504-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| EP-3413977-A1 | DIPEPTIDYL ALDEHYDES FOR THE TREATMENT AND/OR PREVENTION OF PARASITIC DISEASES | Axiava Pharma UG (DE) | 2018-12-19 | — | — | EP | claimed |
| WO-2017137448-A1 | DIPEPTIDYL ALDEHYDES FOR THE TREATMENT AND/OR PREVENTION OF PARASITIC DISEASES | AXIAVA PHARMA UG (DE) | 2017-08-17 | — | — | WO | claimed |
| WO-2026059421-A3 | NOVEL USE OF CATHEPSIN L INHIBITOR | 연세대학교 산학협력단 | 2026-05-07 | — | — | WO | disclosed |
| WO-2026089565-A1 | USE OF CATHEPSIN L INHIBITOR IN COMBINATION ADMINISTRATION | 연세대학교 산학협력단 | 2026-04-30 | — | — | WO | disclosed |
| EP-4724502-A1 | SINGLE DOMAIN ANTIBODIES DIRECTED AGAINST HUMAN TRANSMEMBRANE- SERINE PROTEASE 2 (TMPRSS2) | Institut Pasteur (FR) | 2026-04-15 | — | — | EP | disclosed |
| WO-2026059421-A2 | NOVEL USE OF CATHEPSIN L INHIBITOR | 연세대학교 산학협력단 | 2026-03-19 | — | — | WO | disclosed |
| US-20260053934-A1 | DUAL ACTION ONLY PROTEOLYSIS TARGETING CHIMERAS AND USES THEREOF | UNIV MASSACHUSETTS (US) | 2026-02-26 | — | — | US | disclosed |
| US-12447142-B2 | Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2025-10-21 | — | — | US | disclosed |
| WO-2022072504-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| US-20190030113-A1 | DIPEPTIDYL ALDEHYDES FOR THE TREATMENT AND/OR PREVENTION OF PARASITIC DISEASES | TRICOLUM PHARMACEUTICALS GMBH (AT) | 2019-01-31 | — | — | US | disclosed |
| EP-3413977-A1 | DIPEPTIDYL ALDEHYDES FOR THE TREATMENT AND/OR PREVENTION OF PARASITIC DISEASES | Axiava Pharma UG (DE) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017137448-A1 | DIPEPTIDYL ALDEHYDES FOR THE TREATMENT AND/OR PREVENTION OF PARASITIC DISEASES | AXIAVA PHARMA UG (DE) | 2017-08-17 | — | — | WO | disclosed |
| WO-2002048097-A9 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PARASITIC INFECTIONS | CORVAS INT INC (US) | 2003-05-08 | — | — | WO | disclosed |
| US-20020107266-A1 | Compounds, compositions and methods for treatment of parasitic infections | DENDREON CORPORATION | 2002-08-08 | — | — | US | disclosed |
| WO-2002048097-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PARASITIC INFECTIONS | CORVAS INTERNATIONAL, INC. (US) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12447142-B2 | Compositions and methods for preventing and treating radiation-induced bystander effects caused by radiation or radiotherapy | CTSE, CTSB, ATG4B | CTSL 26/4885CTSB 2/4885CTSS 4/4885 |
| US-20230142126-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | CTSV, CTSB, CTSS | CTSL 13/4885CTSB 2/4885CTSS 3/4885 |
| US-20220143128-A1 | METHODS FOR TREATING TRAUMATIC BRAIN INJURY | CD74, MIF, MICA | CTSL 46/4885CTSB 7/4885CTSS 22/4885 |
| US-20020107266-A1 | Compounds, compositions and methods for treatment of parasitic infections | CAT, CTSA, CTRL | CTSL 26/4885CTSB 6/4885CTSS 5/4885 |
| US-20260053934-A1 | DUAL ACTION ONLY PROTEOLYSIS TARGETING CHIMERAS AND USES THEREOF | PSMA1, PSMB1, PSME1 | CTSL 247/4885CTSB 437/4885CTSS 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.